Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ-Reference-Cited by-同舟云学术

Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ

Published:2018-11-20 Issue:2 Volume:20 Page:164-168
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Baldin G¹^ORCID,Ciccullo A¹^ORCID,Capetti A²,Rusconi S³,Sterrantino G⁴^ORCID,Cossu MV²,Giacomelli A³^ORCID,Lagi F⁴,Latini A⁵,Bagella P⁶,De Luca A⁷,Di Giambenedetto S¹,Madeddu G⁶^ORCID

Affiliation:

1. Institute of Clinical Infectious Diseases; Fondazione Policlinico Universitario A. Gemelli IRCCS; Catholic University of the Sacred Heart; Rome Italy

2. Division of Infectious Diseases; Department of Infectious Diseases; Luigi Sacco University Hospital; Milan Italy

3. Infectious Diseases Unit; DIBIC Luigi Sacco; University of Milan; Milan Italy

4. Division of Tropical and Infectious Diseases; ‘Careggi’ Hospital; Florence Italy

5. Infectious Dermatology and Allergology Unit; IFO S. Gallicano Institute (IRCCS); Rome Italy

6. Department of Clinical and Experimental Medicine; University of Sassari; Sassari Italy

7. University Division of Infectious Diseases; Siena University Hospital; Siena Italy

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hiv.12688/fullpdf

Reference17 articles.

1. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study;Clotet;Lancet,2014

2. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study;Raffi;Lancet,2013

3. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial;Raffi;Lancet Infect Dis,2013

4. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial;Arribas;Lancet Infect Dis,2014

5. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial;Pozniak;Lancet Infect Dis,2014

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Dysregulated Autophagy in HIV Tat, Cocaine, and cART Mediated NLRP3 Activation in Microglia;Journal of Neuroimmune Pharmacology;2023-05-06

2. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review;Expert Review of Anti-infective Therapy;2023-04-20

3. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study;Viruses;2023-03-10

4. Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment;Annals of Medicine;2023-03

5. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic;Viruses;2023-01-24